-
Product Insights
New![]()
Net Present Value Model: Novartis AG’s NIS-793
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NI-1701 in Follicular Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NI-1701 in Follicular Lymphoma Drug Details:NI-1701 (TG-1801) is under development for the treatment of acute lymphocytic...
-
Track & Monitor
![]()
3D printing in defence: Ni-Co alloy 3D Printing
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the defence industry’s Ni-Co alloy 3D Printing within 3D printing innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NI-1701 in B-Cell Non-Hodgkin Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NI-1701 in B-Cell Non-Hodgkin Lymphoma Drug Details:NI-1701 (TG-1801) is under development for the treatment of acute...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NI-1701 in Marginal Zone B-cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NI-1701 in Marginal Zone B-cell Lymphoma Drug Details: NI-1701 (TG-1801) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NI-1701 in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NI-1701 in Diffuse Large B-Cell Lymphoma Drug Details: NI-1701 (TG-1801) is under development for the...
-
Product Insights
![]()
Loma Negra NI Field, Argentina
Loma Negra NI upstream field is located in Neuquen Province, Argentina. The upstream field is owned by Oilstone Energia SA. It is operated by Oilstone Energia SA. The project started its operations in 2009. Loma Negra NI Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs....
-
Product Insights
![]()
NEA/NI Development Upstream Project , Egypt
NEA/NI Development upstream project is located in Mediterranean Sea, Egypt. The upstream project is owned by Edison Exploration & Production SpA; Petro Amriya Co (0%). It is operated by Petro Amriya Co. The project started its operations in 2023. NEA/NI Development Upstream profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: Voyager-V1 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Adenocarcinoma Drug Details: Voyager-V1 is under development for the treatment of metastatic melanoma...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.